Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023-09 · 1878 (5) · 188946
DOI: 10.1016/j.bbcan.2023.188946 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023-09. Verfasst von Sihui Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 272 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Immunogenic cell death (ICD) has been a revolutionary modality in cancer treatment since it kills primary tumors and prevents recurrent malignancy simultaneously. ICD represents a particular form of cancer cell death accompanied by production of damage-associated molecular patterns (DAMPs) that can be recognized by pattern recognition receptors (PRRs), which enhances infiltration of effector T cells and potentiates antitumor immune responses. Various treatment methods can elicit ICD involving chemo- and radio-therapy, phototherapy and nanotechnology to efficiently convert dead cancer cells into vaccines and trigger the antigen-specific immune responses. Nevertheless, the efficacy of ICD-induced therapies is restrained due to low accumulation in the tumor sites and damage of normal tissues. Thus, researchers have been devoted to overcoming these problems with novel materials and strategies. In this review, current knowledge on different ICD modalities, various ICD inducers, development and application of novel ICD-inducing strategies are summarized. Moreover, the prospects and challenges are briefly outlined to provide reference for future design of novel immunotherapy based on ICD effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
- Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; Reproductive Medicine Center, Department of Obstetrics and Gyne…
- Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. Electronic address: zhang.jiarong@zs-hospital.sh.cn.
Förderung
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Yu, S., Xiao, H., Ma, L., Zhang, J., & Zhang, J. (2023). Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878(5), 188946. https://doi.org/10.1016/j.bbcan.2023.188946
Vancouver
Yu S, Xiao H, Ma L, Zhang J, Zhang J. Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(5):188946. doi:10.1016/j.bbcan.2023.188946
BibTeX
@article{Yu2023,
author = {Yu, Sihui and Xiao, Hongyang and Ma, Li and Zhang, Jiawen and Zhang, Jiarong},
title = {Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2023},
volume = {1878},
number = {5},
pages = {188946},
doi = {10.1016/j.bbcan.2023.188946}
}
EUVIMED